---
title: "SSY Group Ltd. Secures Chinese Regulatory Approval for Levamlodipine Besilate Tablets"
description: "SSY Group Ltd. has received approval from China's National Medical Products Administration for Levamlodipine Besilate Tablets in 5mg and 2.5mg strengths. These products are classified as type 4 chemic"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261547083.md"
published_at: "2025-10-17T04:06:21.000Z"
---

# SSY Group Ltd. Secures Chinese Regulatory Approval for Levamlodipine Besilate Tablets

> SSY Group Ltd. has received approval from China's National Medical Products Administration for Levamlodipine Besilate Tablets in 5mg and 2.5mg strengths. These products are classified as type 4 chemical drugs and have passed consistency evaluation. They are used to treat hypertension and angina, either alone or with other medications. This announcement updates shareholders and potential investors on the company's business developments.

SSY Group Ltd. has announced that it has received approvals from the National Medical Products Administration of China for the production and registration of Levamlodipine Besilate Tablets in 5mg and 2.5mg strengths. These approvals classify the products as type 4 chemical drugs and confirm that they have passed the consistency evaluation. Levamlodipine Besilate Tablets are used for the treatment of hypertension, chronic stable angina, and vasospastic angina, and can be administered alone or in combination with other medications. The announcement aims to update shareholders and potential investors on the company’s latest business developments. The approvals pertain solely to SSY Group Ltd. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief on October 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [02005.HK - SSY GROUP](https://longbridge.com/en/quote/02005.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| SSY Group Wins China Approval for New Hypertension Combination Drug | SSY Group Limited has received approval from China's National Medical Products Administration for its Perindopril Argini | [Link](https://longbridge.com/en/news/271492775.md) |
| SSY Group Gets China Nod for Registration of Three Drugs | SSY Group Gets China Nod for Registration of Three Drugs | [Link](https://longbridge.com/en/news/263996667.md) |
| 23:18 ETNovel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF | Shanghai Ark Biopharmaceutical Co., Ltd. announced that the FDA has cleared its IND application for AK3280, a novel anti | [Link](https://longbridge.com/en/news/275698481.md) |
| Florida Health Dept. Proposes New Formal Rule to Slash HIV Drug Access for Thousands, Notes AHF | The Florida Department of Health has proposed a new rule that could significantly reduce access to HIV medications for o | [Link](https://longbridge.com/en/news/275629901.md) |
| 08:01 ETNew "Hypertension Bites" Campaign Urges Adults to Prioritize Blood Pressure Control | The Hypertension Control Alliance has launched the "Hypertension Bites" campaign to raise awareness about the importance | [Link](https://longbridge.com/en/news/275760090.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.